Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Enzalutamide + Abiraterone in mCRPC (Alliance A031201)
NCT01949337Phase 3Unknown
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival up to 5 years. Status: unknown.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01949337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949337.